NOVAVAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.48 USD | +2.82% |
|
+192.41% | +180.83% |
| 14/05 | Global markets live: Apple, Sony, Vodafone, Booking, Walmart... |  |
| 14/05 | Social Buzz: Wallstreetbets Stocks Mostly Higher Pre-Bell Tuesday; AMC Entertainment, GameStop to Advance | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 95Cr 7.94TCr | Sales 2025 * | 59Cr 4.89TCr | Capitalization | 189.28Cr 16TCr |
|---|---|---|---|---|---|
| Net income 2024 * | 1.8Cr 150.2Cr | Net income 2025 * | -12Cr -967.94Cr | EV / Sales 2024 * | 1.11 x |
| Net cash position 2024 * | 84Cr 6.99TCr | Net cash position 2025 * | 70Cr 5.88TCr | EV / Sales 2025 * | 2.03 x |
| P/E ratio 2024 * |
212
x | P/E ratio 2025 * |
-24.5
x | Employees | 1,543 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novavax, Inc.
More recommendations
More press releases
More news
| 1 day | -0.41% | ||
| 1 week | +192.41% | ||
| Current month | +211.32% | ||
| 1 month | +214.95% | ||
| 3 months | +228.78% | ||
| 6 months | +116.03% | ||
| Current year | +180.83% |
1 week
4.43
15.00
1 month
3.8115.00
Current year
3.5315.00
1 year
3.5315.00
3 years
3.53277.80
5 years
3.53331.68
10 years
3.53331.68
| Managers | Title | Age | Since |
|---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23/23/23 |
John Trizzino
PSD | President | 64 | 10/14/10 |
James Kelly
DFI | Director of Finance/CFO | 58 | 16/21/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 29/22/29 |
Gregg Alton
BRD | Director/Board Member | 58 | 01/20/01 |
David Mott
BRD | Director/Board Member | 58 | 16/20/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 17 M€ | +7.01% | - | |
| 0.15% | 0 M€ | 0.00% | - | |
| 0.13% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/24/14 | 13.48 | +2.82% | 56,549,364 |
| 13/24/13 | 13.11 | +47.64% | 123,507,768 |
| 10/24/10 | 8.88 | +98.66% | 170,871,994 |
| 09/24/09 | 4.47 | 0.00% | 4,533,199 |
| 08/24/08 | 4.47 | -3.04% | 3,080,374 |
Delayed Quote Nasdaq, May 15, 2024 at 01:30 am IST
More quotes
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Calendar
06/08/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
13.48
USD
Average target price
19.75
USD
Spread / Average Target
+46.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +180.83% | 189.28Cr | |
| +29.03% | 4.92TCr | |
| -0.10% | 4.21TCr | |
| +46.90% | 4.04TCr | |
| -5.26% | 2.89TCr | |
| +11.48% | 2.61TCr | |
| -22.74% | 1.87TCr | |
| +9.06% | 1.33TCr | |
| +30.01% | 1.23TCr | |
| -1.51% | 1.2TCr |
- Stock Market
- Equities
- NVAX Stock